Dana-Farber’s Breast Oncology Center shared on X:
“The SATEENtrial led by Dana-Farber’s Breast Oncology Center is a multi-center, single-arm phase II trial to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab for HER2+ Metastatic Breast Cancer.
For more information call 877-338-7425 or visit.”
